Vaxine allergy vaccine

Vaxine Pty Ltd is developing a range of allergy vaccines utilizing its proprietary Advax adjuvant technology. Advax is a unique polysaccharide adjuvant derived from delta-inulin that is designed to enhance immune responses without the pro-inflammatory side effects typically associated with traditional adjuvants like alum. In the context of allergy treatment, the vaccine aims to redirect the immune system's response away from the Th2-mediated allergic pathway (associated with IgE production and allergic symptoms) toward a Th1-mediated protective pathway. This immunomodulatory approach is intended to provide a safer and more effective alternative to traditional allergen immunotherapy (AIT), potentially offering long-term desensitization. The program includes research into vaccines for various allergens, including insect venoms (such as honeybee venom) and food allergies (such as peanut allergy).

Other names

Advax-adjuvanted allergy vaccineVaxine allergy immunotherapy